Publications

November 2005 (Revised March 2006)
Case

Genentech - Capacity Planning

By: Daniel C. Snow, Steven C. Wheelwright and Alison Berkley Wagonfeld

While facilitating a complex clinical approval process over the next two to three years for a family of new cancer drugs, Genentech must develop a long-term capacity plan for a major class of new cancer products. Adding to the complexity and uncertainty is the fact... View Details

Keywords: Factories, Labs, and Plants; Growth and Development Strategy; Management Style; Management Teams; Time Management; Product; Product Development; Business Processes; Performance Capacity; Planning; Risk and Uncertainty; Complexity; Pharmaceutical Industry

April 2009
Case

Merck: Managing Vioxx (A)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details

Keywords: Ethics; Crisis Management; Reputation; Decision Choices and Conditions; Customers; Business or Company Management; Cost vs Benefits; Corporate Accountability; Business and Shareholder Relations; Business and Stakeholder Relations; Customer Focus and Relationships; Pharmaceutical Industry

November 2006 (Revised May 2025)
Case

Eli Lilly: Developing Cymbalta

By: Elie Ofek and Ron Laufer

Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details

Keywords: Decision Choices and Conditions; Marketing Strategy; Product Launch; Product Development; Research and Development; Pharmaceutical Industry

October 2021 (Revised October 2022)
Case

The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni

In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details

08 Feb 2000
Research & Ideas

Building Effective R&D Capabilities Abroad

capabilities and product portfolio, the company needed a dedicated laboratory site in East Asia. The new site would support efforts to manufacture and market pharmaceuticals by adapting products to local needs. To that end, the management... View Details

Keywords: by Walter Kuemmerle

February 2024
Article

Representation and Extrapolation: Evidence from Clinical Trials

By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams

This article examines the consequences and causes of low enrollment of Black patients in clinical trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is more relevant for decision-making by physicians and patients when it... View Details

Keywords: Representation; Racial Disparity; Health Testing and Trials; Race; Equality and Inequality; Innovation and Invention; Pharmaceutical Industry

01 Oct 2001
News

Guy de Chazal: Changing Focus

Fountain House board member since 1986, he speaks with deep conviction about the challenges faced by the emotionally handicapped. "With advances in pharmaceutical treatments for emotional illnesses, hospitalization is no longer the right... View Details

Keywords: Deborah Blagg

15 Dec 2003
Research & Ideas

The New Global Business Manager

The other is free. Through Project Hope, they seek out people who are suffering from this disease, in Africa or China, for example, and provide the therapy. This approach is in stark contrast to some of the big pharmaceutical companies... View Details

Keywords: by Cynthia Churchwell

June 2014 (Revised September 2014)
Case

Johnson & Johnson: The Promotion of Wellness

By: John A. Quelch and Carin-Isabel Knoop

To create the world's healthiest workforce, diversified health care giant Johnson & Johnson (J&J) mandated participation in its "Culture of Health" program globally, customized by location, culture, and specific health needs to offer prevention-focused education,... View Details

Keywords: Healthcare; Employee Motivation; Transformation; Ethics; Health; Human Resources; Leadership; Management; Personal Development and Career; Problems and Challenges; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Middle East; Latin America; Europe; Asia

Web

General Management Awards & Honors - Faculty & Research

Strategic Management Society for her paper with Ian Cockburn, "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research" ( Strategic Management Journal , 1994). The award is for a paper published five or more years prior so... View Details

31 Jan 2014
News

Body, Heal Thyself

for the development and exclusive use of the mRNA technology to treat cardiovascular, renal, and metabolic diseases as well as cancer. "It is one of the largest-ever initial payments in a pharmaceutical industry licensing deal that does... View Details

Keywords: Maureen Harmon; biotech; Health, Social Assistance; Scientific Research and Development Services

June 2023 (Revised June 2023)
Supplement

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details

January 2014 (Revised June 2015)
Case

Amgen Inc.: Pursuing Innovation and Imitation? (A)

By: Ian W. Mackenzie

Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:... View Details

Keywords: Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

10 Aug 2015
Research & Ideas

New Medical Devices Get To Patients Too Slowly

While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of medical devices. Instead of... View Details

Keywords: by Michael Blanding; Health; Technology

January 2017
Case

Danaher Corporation, 2007–2017

By: John R. Wells and Gabriel Ellsworth

On July 2, 2016, Danaher Corporation completed the spinoff of Fortive Corporation. The previous day, Danaher’s stock price had reached an all-time high. In 2015, Danaher had decided to split off its test and measurement, fuel and fleet management, and automation... View Details